By Byron Kaye SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight ...

It was once feared weight-loss drugs would crush demand for sleep apnoea products. ResMed's December quarter has shown very ...

Resmed, a leading health technology company focusing on sleep and respiratory care, has become the Official Sleep Partner for the Qatar Airways British & Irish Lions Tour to Australia, set to take ...

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on ...

In key news on Australian stocks, ResMed Inc. (NYSE:RMD) (AU:RMD) surged nearly 8% as of writing, driven by the company’s robust Q3 results for FY24. The company’s third-quarter performance reflected ...

ResMed’s latest result highlights improved profitability and continued resilience in sleep and respiratory care markets, ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $279.86, with a ...

Resmed posts double-digit revenue and profit growth in Q2 FY26, declares dividend, and outlines plans for innovation. The post Resmed posts Q2 FY26 earnings growth, lifts dividend appeared first on ...

Analysts estimate that ResMed will report an earnings per share (EPS) of $2.71. The announcement from ResMed is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

RMD is set to report Q2 results on Jan. 29, with revenues likely to jump 8.3% and EPS 10.3% as masks, devices and software drive growth.

SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been ...